This phase I trial is trying to understand whether a new intra-muscular treatment is safe and tolerable when given alone or in combination with immunotherapy for the treatment of small cell lung cancer, colorectal cancer or pancreatic cancer.
This trial is treating multiple types of cancer including non-small cell lung cancer, colorectal cancer or pancreatic cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
Eligible patients will be assigned to one of two experimental groups, receiving V941 either as a monotherapy for 9 3-week cycles or in combination with pembrolizumab for 35 3-week cycles.
Recruiting Hospitals Read More